Cybin Inc. Unveils Promising Psychedelic Research

TipRanksApr 18 20:17

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

- Publication explores structure-activity relationships ("SAR") of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist

BusinesswireApr 18 19:30

Cedar Clinical Research Selected as Clinical Research Site for Cybin's Phase 3 Study of CYB003

VANCOUVER, BC, April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behaviora

PR NewswireApr 17 19:00

Cybin Inc. Secures Patent, Progresses MDD Therapy

TipRanksApr 16 20:09

Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder

Cybin Announces Grant Of Additional US Patent In Support Of Its CYB003 Breakthrough Therapy Program For Major Depressive Disorder

BenzingaApr 16 19:35

Cybin Announces Grant of Additional U.S. Patent in Support of Its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder ("MDD").

BusinesswireApr 16 19:30